Weekly Recap | Twist Bioscience -2.89%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.Twist Bioscience fell 2.89% on the week, closing at $141.38. The week started with a dip to $137.37 on Monday before three straight up days pushed the stock to a Thursday high of $155.44. Friday reversed sharply, ending near the week’s low. Daily amplitude reached 12.43%, with average daily volume around 1.55m shares, slightly below the 60-day median, suggesting the swings were driven by intraday positioning rather than sustained flows.
The Week
Twist Bioscience fell 2.89% on the week, closing at $141.38. The week started with a dip to $137.37 on Monday before three straight up days pushed the stock to a Thursday high of $155.44. Friday reversed sharply, ending near the week’s low. Daily amplitude reached 12.43%, with average daily volume around 1.55m shares, slightly below the 60-day median, suggesting the swings were driven by intraday positioning rather than sustained flows.
Key Events
The most direct development was CEO Emily Leproust’s disclosure of selling roughly $6.28m in common shares on Friday. Earlier in the week, the stock jumped 9.53% intraday on Wednesday, with market commentary linking the move to inflows into AI-driven drug development names. The same day brought industry news that HHS is considering two new FDA deputy commissioners focused on technology and drugs. The week’s earlier pieces centred on infrastructure value chains and AI market structure, with limited direct read-through to Twist.
Analyst Ratings
Eleven firms cover the stock: seven rate it buy, two rate it overweight, and two rate it hold, with no underweight or sell ratings. The consensus rating is buy, with a consensus target of $105.30, about 25.5% below the current price. Target prices range from $36 to $120, pointing to wide dispersion. Among 505 companies in the industry, its rating rank sits at 116. The consensus target below spot suggests broker price assumptions have not caught up with the recent run-up.
The Week Ahead
The week ahead is macro-heavy. Tuesday brings the ISM manufacturing PMI (prior 55.6, forecast 55.2), JOLTS job openings, and the S&P Global manufacturing PMI final. Wednesday adds ADP private payrolls and factory orders. No company earnings date is yet disclosed, so the focus falls on whether volume stabilises after this week’s sharp moves and whether further insider transactions are reported following the CEO sale.
In Short
The tension this week sits between broadly buy-rated broker coverage, a consensus target below spot, a CEO share sale, and a sharp Friday pullback. The stock trades at roughly 19.9x book with negative earnings, while the latest session’s flow showed large-lot money as net seller and small-to-mid lots as net buyer. What to watch is whether the recent pulse-like swings give way to steadier positioning, and whether macro data adds pressure to high-valuation growth names.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.